Truxima Approved as First Biosimilar to Non-Hodgkin's Lymphoma Drug

WEDNESDAY, Nov. 28, 2018 — Truxima (rituximab-abbs) has been approved by the U.S. Food and Drug Administration as the first biosimilar to the non-Hodgkin’s lymphoma drug Rituxan, the agency said Wednesday.
A biosimilar is a biological product that…
Source: Topamax